glp 1 commercial Serena Williams Is the Surprising New Face of Weight-Loss Drugs Serena Williams stars in Ro's

GLP-1 is a naturally-occurring hormone made in the small intestine

no validated biomarker tracking exists

long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts

A total of 50 women were accepted into the study with half being given NAC 600 mg/day for 3 months and the other half the placebo

Abbreviations CKD: Chronic kidney disease DKA: Diabetic ketoacidosis FDA: US Food and Drug Administration GLP-1 RA: Glucagon-like peptide-1 receptor agonist HCO: Healthcare organisation IHD: Ischaemic heart disease PSM: Propensity score matching SGLT2i: Sodium-glucose cotransporter 2 inhibitor SSMD: Strictly standardised mean difference UTI: Urinary tract infection References Gregory GA, Robinson TIG, Linklater SE et al (2022) Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study